Photo taken from
Rami Manochakian/X
Apr 13, 2024, 09:40
Rami Manochakian: Results of adjuvant Alectinib vs Chemotherapy in resected ALK+ stage IB-IIIA NSCLC
Rami Manochakian, thoracic medical oncologist at Mayo Clinic, shared a post on X:
“Hot off the press.
Just published at NEJM.
Results of ALINA phase 3 trial of adjuvant Alectinib vs Chemotherapy in patients with resected ALK+ stage IB-IIIA Non-Small-Cell Lung Cancer showing: DFS HR: 0.24
2-year DFS: 93% vs 63%”
Source: Rami Manochakian/X